论文部分内容阅读
我们试用熊去氧胆酸(UDCA)治疗慢性肝炎64例,对照组48例,随访观察半年。结果:治疗组总有效率达89.06％,对照组为64.58％,治疗前、后观察肝功、免疫球蛋白(IgG、IgM)、血清免疫复合物(CIC)及乙肝标记物(HBsAg/IgM、HBeAg、抗HBc IgM),治疗组各项指标改善均优于对照组。经临床验证,我们认为UDCA老药新用治疗慢性肝炎疗效肯定,无明显副作用,为治疗慢性肝炎开辟了一条新途径。
We tried ursodeoxycholic acid (UDCA) treatment of chronic hepatitis in 64 cases, 48 cases of control group, followed up for six months. Results: The total effective rate was 89.06% in the treatment group and 64.58% in the control group. The liver function, immunoglobulin (IgG, IgM), serum immunocomplex (CIC) and hepatitis B (HBsAg / IgM) HBeAg, anti-HBc IgM), the treatment group improved better than the control group. The clinical validation, we believe that the new drug UDCA treatment of chronic hepatitis with certain efficacy, no obvious side effects, for the treatment of chronic hepatitis opened up a new way.